Phentermine stopped working: tolerance is not every plateau
The phentermine label specifically warns about tolerance to its anorectic effect. A slower scale trend alone does not prove pharmacologic tolerance; a prescriber needs the full course, appetite changes, and response record.
A weight plateau while taking phentermine does not, by itself, prove drug tolerance. The phentermine capsule label describes tolerance to its appetite-related effect, while a scale trend measures a different outcome. A prescriber needs the treatment course, appetite history, tolerability, and weight record together to assess what has changed.1
The question “why did it stop working?” can refer to at least three observations: the medicine feels different, appetite has changed, or measured weight loss has slowed. Those observations can occur together, but they are not identical. An answer that treats them as interchangeable skips the clinical question of which effect has actually changed.
Define what changed before calling it tolerance
| What changed | What the record can show | What it cannot prove alone |
|---|---|---|
| Appetite-related effect feels weaker | A patient's report over time | The mechanism or a treatment decision |
| Scale trend slows or levels | A dated sequence of measurements | That phentermine's anorectic effect has disappeared |
| Weight rises after a prior decline | A change in measured trajectory | Why the change occurred or whether a medicine caused it |
| Adverse effect or new symptom | A reason to contact the prescriber | Whether the drug should be changed without clinical assessment |
The current label describes phentermine as a short-term adjunct. Its section 5.4 specifically addresses tolerance to the anorectic effect. It does not define tolerance as any single week without weight loss. That is why the prescriber should assess the reported appetite effect and the weight record as separate pieces of evidence.1
The label also notes that weight-loss rates are often greatest early in treatment for both drug and placebo groups in the short trials it discusses. A slower later trend is therefore not, by itself, a unique sign of a drug’s pharmacologic effect disappearing.1
A research definition is not the label definition
An open-label observational study of phentermine used an operational definition tied to weight reduction from one month to the next. It explored whether early loss and later “tolerance” by that definition predicted a six-month group outcome. That is a research method for analyzing weight curves, not a validated at-home test for the label’s anorectic-effect tolerance.2
The study has limited ability to identify cause. It followed a particular population and regimen without a randomized placebo comparison for the question being asked. Weight trends reflect many factors besides one medicine. Its percentages should not be used to classify an individual’s response or set a universal reassessment schedule.
When a website equates “one flat week” with “your receptors are saturated,” ask what primary source supports the mechanism and timeframe. The label’s actual topic is a change in appetite-related effect; a prescriber can evaluate whether that concern fits the person’s course.1
Prepare a useful follow-up record
Write down the exact product and prescribed course, the dates of treatment and follow-up, and what outcome the prescriber originally intended to assess. Include a dated weight trend rather than a single “before” and “after” number. Describe appetite and tolerability in ordinary words without trying to diagnose the mechanism.
Add any relevant changes in other medicines, sleep, activity, illness or routine. The clinician can decide which are meaningful. Do not omit adverse effects because the scale was moving in the desired direction. A treatment is not judged solely by one number.
If the practice recommended phentermine as part of a package, ask which named clinician owns the review and how the package handles a change in effect. A subscription that automatically renews the prescription without a clinical check cannot answer this question.
Three decisions belong to the prescriber
Is the current response adequate for the original goal? The answer depends on the full course, tolerability and health context. An online target percentage taken from a different trial is not the person’s care plan.
Does the label’s tolerance concern apply? That requires distinguishing subjective appetite effect from scale trajectory and considering the exact product. A flat trend does not answer the question on its own.1
What is the next weight-care question? The prescriber can explain whether the original goal, response record, or another factor deserves attention. The phentermine-versus-Qsymia guide explains why another product is not merely a longer-acting version of phentermine.
At a medical weight-management consultation, bring the product record and the trend. Ask the prescriber to explain whether the issue is a changed appetite effect, a weight plateau, a safety concern, or a change in the original goal, and who will follow up. That gives the concern a documented clinical review instead of a guessed explanation from one scale reading.
Sources
- National Library of Medicine DailyMed. Phentermine hydrochloride capsule prescribing information. Section 5.4 distinguishes tolerance to the anorectic effect; the label describes the product as a short-term weight-management adjunct. A scale plateau alone is not the label's definition. Accessed .
- PubMed / Journal of Personalized Medicine. First-month weight loss and phentermine tolerance as predictors at six months. Original open-label study used an operational weight-trend definition of tolerance that differs from the label's anorectic-effect wording; it cannot diagnose an individual's loss of effect. Accessed .